Fulcrum Therapeutics (FULC)
(Real Time Quote from BATS)
$8.52 USD
+0.38 (4.67%)
Updated Jun 5, 2024 03:04 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Price, Consensus and EPS Surprise
FULC 8.52 +0.38(4.67%)
Will FULC be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for FULC based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for FULC
The Zacks Analyst Blog Highlights Novavax, Sanofi, Fulcrum Therapeutics, Moderna and Bristol Myers
Biotech Stock Roundup: NVAX, FULC Up on Deals With SNY, Updates From MRNA, BMY
FULC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts See a 69.15% Upside in Fulcrum Therapeutics (FULC): Can the Stock Really Move This High?
Ginkgo Bioworks Holdings, Inc. (DNA) Reports Q1 Loss, Lags Revenue Estimates
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Tops Revenue Estimates
Other News for FULC
Biotech Alert: Searches spiking for these stocks today
Goldman Sachs Predicts up to 108% Rally for These 2 ‘Strong Buy’ Stocks
Fulcrum Therapeutics (NASDAQ:FULC) Readies Phase 3 Candidate with Blockbuster Potential
Rubrik and Marex Group initiated: Wall Street's top analyst calls
Cantor starts Fulcrum with Overweight ahead of Q4 data